Overview

A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer

Status:
Not yet recruiting
Trial end date:
2028-10-20
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to compare the clinical benefit, as measured by Progression-Free Survival (PFS), achieved by HX008 or Investigator's Choice Chemotherapy in participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) metastatic colorectal cancer (mCRC).
Phase:
Phase 3
Details
Lead Sponsor:
Taizhou Hanzhong biomedical co. LTD